QLGN
NASDAQQualigen Therapeutics Inc.
Qualigen Therapeutics Inc. (QLGN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for QLGN in the last 30 days. The most recent was published Nov 21, 2025.
Latest news
25 items- SECSEC Form 8-K filed by Qualigen Therapeutics Inc.8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)
- SECQualigen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)
- SECSEC Form 8-K filed by Qualigen Therapeutics Inc.8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Qualigen Therapeutics Inc.SCHEDULE 13D/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)
- SECQualigen Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- PRQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyShareholders approved all proposals, confirming Faraday Future Intelligent Electric Inc. ("Faraday Future") as the Company's new majority and controlling shareholder.Faraday Future will nominate a majority of board seats prior to November 20 as part of the Company's strategic transformation.The Company will host an official renaming and ticker activation ceremony at Nasdaq Headquarters in New York on November 20, adopting the new ticker symbol AIXC.During the ceremony, the Company will unveil a new business model, ecosystem structure, and three-year development roadmap positioning AIxCrypto as a leading gateway to the AI × Web3 era.The transition introduces cross-ecosystem enablement between
- SECSEC Form 10-Q filed by Qualigen Therapeutics Inc.10-Q - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Qualigen Therapeutics Inc.SCHEDULE 13G/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)
- PRQualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ:QLGN) ("Qualigen", "QLGN" or the "Company"), a publicly-traded technology company majority owned by Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future" or "FF"), today announced that it will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025. AIxCrypto's Strategic Roadmap QLGN (soon to be AIxCrypto) has launched its new Web3 and crypto asset business initiatives. Following its targeted rebranding on November 12, the Company will launch the public beta of its BesTrade DeAI Agent by the end of November and release its EAI RWA Utility Token Whitepap
- PRQualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury AllocationNew York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ:QLGN) ("Qualigen", "QLGN" or "Company"), a publicly-trading technology company majority owned by Faraday Future, today announced a strategic partnership with BitGo, the digital asset infrastructure company, to support its C10 treasury strategy, which accumulate and compound a market-cap-weighted basket of the world's top 10 crypto assets (excluding stablecoins). Through this partnership, Qualigen will leverage BitGo's holistic treasury management offering1 that combines access to deep liquidity with secure qualified custody. BitGo's OTC desk will enable Qualigen to efficiently invest across a diversified ba
- SECSEC Form DEF 14A filed by Qualigen Therapeutics Inc.DEF 14A - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- PRQualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases: Why is this pullback the golden moment CXC10 has been waiting for? The past 48 hours have been brutal for the entire crypto market. Amidst the market's turbulent volatility, approximately $16 billion in leveraged positions were forcibly liquidated, leaving many investors helpless to prevent a significant decline in their paper wealth. In times of widespread panic, we must remain calm. Declines often present opportunities. As Buffett famously said, "When others are greedy, I am fearful; when othe
- SECSEC Form PRE 14A filed by Qualigen Therapeutics Inc.PRE 14A - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- SECSEC Form 8-K filed by Qualigen Therapeutics Inc.8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- SECQualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- PRUnivest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)New York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $41 million strategic investment in its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen Therapertics"), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, from its client Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company. The total investment amounts to approximately $41 million
- PRQualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into CryptoCarlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or "the Company") today announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("FF"), along with its Founder and Global Co-CEO YT Jia, President Jerry Wang, SIGN Foundation – a blockchain technology company backed by Binance Labs, Sequoia Capital (US, India, China), IDG, and Circle, and other leading investors. FF has invested $30 million in QLGN common and preferred stock, representing approximately 55% of pro forma beneficial ownership. YT Jia, has personally invested approxim
- PRFaraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco StrategyQLGN is expected to rebrand as CXC10 soon, reflecting its new strategic direction around crypto and web3 business. LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced the successful closing of its announced strategic investment in Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a public company establishing new crypto and Web3-related adventures. The total investment amounts to approximately $41 million, led by FF with approximately $30 million, and an additional $4 million invested by FF Founder and Global
- SECQualigen Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- SECSEC Form EFFECT filed by Qualigen Therapeutics Inc.EFFECT - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- SECQualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- SECSEC Form RW filed by Qualigen Therapeutics Inc.RW - Qualigen Therapeutics, Inc. (0001460702) (Filer)
- PRFaraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth EnginesFaraday Future is making an investment of approximately $30 million in Qualigen Therapeutics ("QLGN"); FF Founder and Co-CEO YT Jia will invest approximately $4 million (via an FFGP loan) in QLGN with a two-year lockup.The strategic investment, which was announced at the Company's annual 919 event held in Los Angeles on Sept. 19, accelerates the progress of the "Dual-Flywheel & Dual-Bridge" Eco Strategy to maximize stockholder value. QLGN expects to rebrand as CXC10, focusing on three growth engines with six potential major products for crypto/Web3 ecosystem build-ip, targeting to become atop U.S. public company bridging Web2 and Web3, as well as AI and crypto.As of 6 p.m. on September 18, t
- PRFaraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE TransactionLOS ANGELES and CARLSBAD, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("QLGN"), jointly announced that they have entered into a securities purchase agreement (the "Agreement") for a private investment in public equity (PIPE) in QLGN's common stock and preferred stock, and will start a crypto and web3-related business. Upon completion of the required stockholder approval process, it is expected that QLGN will rebrand as CXC10, fully focusing on its three growth engines i
- PRFaraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE TransactionLOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("QLGN"), jointly announced that they have entered into a securities purchase agreement (the "Agreement") for a private investment in public equity (PIPE) in QLGN's common stock and preferred stock, and will start a in Crypto and web3-related business. The PIPE financing is being led by Faraday Future and its Founder and Global Co-CEO YT Jia, together with other investors including SIGN Foundation, a blockchain
QLGN FAQ
7 questionsWhat does Qualigen Therapeutics Inc. do?
Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen...What is the latest news on QLGN?
Quantisnow has not tracked any new filings, ratings or press releases for QLGN in the last 30 days. The most recent wire item was published on November 21, 2025.Where does QLGN stock trade?
Qualigen Therapeutics Inc. (QLGN) is listed on NASDAQ.What sector and industry is QLGN in?
Qualigen Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Qualigen Therapeutics Inc. go public?
Qualigen Therapeutics Inc. (QLGN) completed its IPO in 2015.What companies are similar to QLGN?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare QLGN side-by-side with any of them on Quantisnow.How can I track QLGN on Quantisnow?
Quantisnow aggregates Qualigen Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QLGN to receive live email and push alerts on every new disclosure.